Gemcitabine

A deoxycytidine antimetabolite used as an antineoplastic agent.

Also Known As:

2',2'-DFDC; Gemzar; LY 188011; LY-188011; dFdCyd; 188011, LY; 2' Deoxy 2' Difluorocytidine; 2' Deoxy 2',2'' Difluorocytidine 5' O Monophosphate; Hydrochloride, Gemcitabine; 2',2'-Difluoro-2'-Deoxycytidine; 2',2'-Difluorodeoxycytidine; 2'-Deoxy-2',2''-Difluorocytidine-5'-O-Monophosphate; 2'-Deoxy-2'-Difluorocytidine; Gemcitabine Hydrochloride; Gemcitabine, (D-threo-pentafuranosyl)-Isomer; Gemcitabine, (alpha-D-threo-pentofuranosyl)-Isomer; Gemcitabine, (beta-D-threo-pentafuranosyl)-Isomer; Gemicitabine

Networked: 13202 relevant articles (2068 outcomes, 4646 trials/studies)

Relationship Network

Drug Context: Research Results

Heterocyclic Compounds: 198
- Gemcitabine: 13202
- 1-Ring Heterocyclic Compounds
  - Pyrimidines: 510
    - Pyrimidine Nucleosides: 50
      - Cytidine: 535
        Deoxycytidine: 307
        Gemcitabine: 13202

Experts

1.	Saif, Muhammad Wasif: 85 articles (03/2021 - 07/2005)
2.	Okusaka, Takuji: 80 articles (01/2022 - 12/2002)
3.	Furuse, Junji: 75 articles (07/2022 - 01/2005)
4.	Ikeda, Masafumi: 56 articles (01/2022 - 01/2005)
5.	Ueno, Hideki: 48 articles (02/2022 - 01/2005)
6.	Peters, Godefridus J: 48 articles (01/2021 - 02/2002)
7.	Giovannetti, Elisa: 46 articles (01/2022 - 05/2004)
8.	Ishii, Hiroshi: 41 articles (01/2022 - 01/2005)
9.	Von Hoff, Daniel D: 41 articles (01/2020 - 11/2002)
10.	Sasaki, Takashi: 40 articles (08/2022 - 01/2008)

Related Diseases

1.	Pancreatic Neoplasms (Pancreatic Cancer) 01/01/2009 - "Single-agent gemcitabine has been established as standard treatment for advanced pancreatic cancer since clinical studies have shown an improvement in overall survival and significant clinical benefit when compared to the best supportive care despite low overall objective response. " 10/26/2021 - "Gemcitabine is the first-line treatment for patients with pancreatic cancer (PC), yet most patients develop resistance to gemcitabine. " 09/01/2012 - "Gemcitabine is currently the best treatment available for pancreatic cancer (PaCa); however, patients with the disease develop resistance to the drug over time. " 05/01/2011 - "Gemcitabine is currently the best treatment available for pancreatic cancer, but causes high toxicity. " 04/15/2007 - "Gemcitabine is currently the best treatment available for pancreatic cancer, but the disease develops resistance to the drug over time. "
2.	Neoplasms (Cancer) 02/01/2022 - "Furthermore, we observed that combining COS with Gemcitabine (GEM), one of the typical chemotherapeutic drugs, leaded to a more remarkable tumor remission. " 11/01/2018 - "Although effective in most patients, development of tumor resistance to gemcitabine can critically limit its efficacy. " 01/01/2018 - "Without overt toxicity, addition of WEE1i to low-dose gemcitabine and CHK1i was most effective in tumor control compared with single and double agents. " 10/15/2010 - "The squalenoylation drug delivery strategy might, therefore, dramatically improve the efficacy of gemcitabine on transporter-deficient resistant cancer in the clinical context." 11/01/2008 - "Gemcitabine fulfills all requirements as an alternative agent in treating BCG failure patients with low adverse events, well tolerated, and highly effective in reducing tumor recurrences."
3.	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 12/05/2005 - "Although gemcitabine is a potent therapeutic agent in the treatment of human non-small cell lung cancer (NSCLC), resistance to gemcitabine is common. " 07/01/1999 - "Following the diagnosis of non-small cell lung carcinoma and subsequent treatment with gemcitabine (a second-line chemotherapeutic agent), a significant reduction in both tumour mass and mucosal blistering was observed. " 07/01/2017 - "A prospective study was conducted to investigate the efficacy of a combined regimen of gemcitabine and S-1 for the treatment of elderly patients (>70 years) with advanced non-small cell lung cancer (NSCLC) as a first-line setting based on the dosage recommended in a previous phase I study. " 03/01/2013 - "When less is better: the safety and efficacy of reduced intensity gemcitabine in a difficult patient population with advanced non-small-cell lung cancer." 05/01/1996 - "As the efficacy of gemcitabine in non-small cell lung cancer was equivalent when using both regimens, the better tolerated and more easily administered once-weekly schedule is recommended."
4.	Adenocarcinoma 03/01/2020 - "However, two additional compounds, 12b and 13g, displayed remarkable in vitro antiproliferative activity against pancreatic ductal adenocarcinoma (PDAC) cell lines, including immortalized (SUIT-2, Capan-1, Panc-1), primary (PDAC-3) and gemcitabine-resistant (Panc-1R), eliciting IC50 values ranging from micromolar to sub-micromolar level, associated with significant reduction of cell-migration and spheroid shrinkage. " 12/01/2017 - "There are limited therapeutic options for treatment-refractory pancreatic ductal adenocarcinoma (PDAC), with a paucity of data to support the best option after progression on gemcitabine-based regimens. " 01/01/2006 - "Clinically relevant improvement in QOL from baseline was observed more often after PEFG than after gemcitabine, suggesting that the PEFG regimen did not impair QOL, Partial response was associated with improved QOL suggesting that effective treatment of pancreatic adenocarcinoma may have an important role in these patients." 08/01/2016 - "This holds significant potential in augmenting efficacy of gemcitabine in treatment of locally advanced and borderline resectable pancreatic adenocarcinoma. " 11/07/2019 - "Both gemcitabine and fluoropyrimidine are recommended backbones in the first-line treatment of pancreatic ductal adenocarcinoma (PDAC). "
5.	Breast Neoplasms (Breast Cancer) 01/01/2017 - "Therapeutic efficacy of gemcitabine, which is used for breast cancer treatment, is severely compromised due to its rapid plasma degradation. " 12/01/2013 - "Our study is the first to demonstrate the pleiotropic effects of Gemcitabine and Gemcitabine-loaded nanoparticles in breast cancer, and opens the door for a novel treatment for breast cancer patients." 02/01/2010 - "This phase II study was designed to assess the efficacy of Gemcitabine (GEM) and PEM given in a novel schedule in metastatic breast cancer (MBC) patients. " 03/01/2021 - "This study aimed to investigate the efficacy of first-line gemcitabine monotherapy for metastatic breast cancer (MBC) and its effect on health-related quality of life (HRQoL) compared with treatment of physician's choice (TPC). " 01/01/2016 - "The aims of this study were to assess the efficacy of the combination of src inhibition and gemcitabine in gemcitabine-resistant breast cancer cells. "

Related Drugs and Biologics

1.	Cisplatin (Platino)
2.	130-nm albumin-bound paclitaxel
3.	Paclitaxel (Taxol)
4.	Docetaxel (Taxotere)
5.	Fluorouracil (Carac)
6.	Carboplatin (JM8)
7.	Oxaliplatin (Eloxatin)
8.	Platinum
9.	Vinorelbine (Navelbine)
10.	folfirinox

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Therapeutics
3.	Combination Drug Therapy (Combination Chemotherapy)
4.	Radiotherapy
5.	Neoadjuvant Therapy